Melissa L Fishel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6910716/publications.pdf

Version: 2024-02-01

86	4,034	145106	139680
papers	citations	33 h-index	61 g-index

91	91	91	5604
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue. Genes and Diseases, 2023, 10, 267-283.	1.5	4
2	Hypoxia signaling: Challenges and opportunities for cancer therapy. Seminars in Cancer Biology, 2022, 85, 185-195.	4.3	17
3	RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostasis in Mouse PDAC Cells. Frontiers in Oncology, 2022, 12, 826617.	1.3	5
4	Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biology, 2022, 23, 113.	3.8	48
5	Abstract 2366: Inhibition of Ref-1/APE1 redox activity with APX3330 enhances Ref-1/APE1 protein unfolded conformation in human PDAC cells. Cancer Research, 2022, 82, 2366-2366.	0.4	0
6	The multifunctional APE1 DNA repairâ€“redox signaling protein as a drug target in human disease. Drug Discovery Today, 2021, 26, 218-228.	3.2	61
7	Combined inhibition of Refâ€1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour coâ€culture models. Journal of Cellular and Molecular Medicine, 2021, 25, 784-800.	1.6	9
8	Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. British Journal of Cancer, 2021, 124, 1566-1580.	2.9	12
9	A graph neural network model to estimate cell-wise metabolic flux using single-cell RNA-seq data. Genome Research, 2021, 31, 1867-1884.	2.4	60
10	Abstract 2475: Differential sensitivity of mouse PDAC KrasG12Dcells to Ref-1/APE1 redox signalling inhibitors: Role of NFkB as a primary target of Ref-1/APE1 inKrasdriven pancreatic ductal adenocarcinoma. , 2021, , .		0
11	Abstract 1088: Advancing non-cytotoxic DNMT1-targeting to treat chemorefractory pancreatic cancer. , 2021, , .		0
12	Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target. Journal of Experimental and Clinical Cancer Research, 2021, 40, 251.	3.5	23
13	Biomimetic stiffening of cell-laden hydrogels via sequential thiol-ene and hydrazone click reactions. Acta Biomaterialia, 2021, 130, 161-171.	4.1	13
14	Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Frontiers in Oncology, 2021, 11, 749496.	1.3	13
15	APE1/Ref-1 - One Target with Multiple Indications: Emerging Aspects and New Directions. Journal of Cellular Signaling, 2021, 2, 151-161.	0.5	3
16	Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions. Journal of Cellular and Molecular Medicine, 2021, 25, 11039-11052.	1.6	7
17	Regulation of cellular sterol homeostasis by the oxygen responsive noncoding RNA lincNORS. Nature Communications, 2020, 11, 4755.	5.8	12
18	Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data. ACS Chemical Biology, 2020, 15, 1424-1444.	1.6	4

#	Article	IF	Citations
19	Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. Cancer Research, 2020, 80, 3101-3115.	0.4	77
20	LTMG: a novel statistical modeling of transcriptional expression states in single-cell RNA-Seq data. Nucleic Acids Research, 2019, 47, e111-e111.	6.5	46
21	Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. Journal of Medicinal Chemistry, 2019, 62, 2651-2665.	2.9	28
22	Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer. Molecular Cancer Therapeutics, 2019, 18, 1947-1960.	1.9	29
23	Abstract C017: Signaling through Ref-1 and STAT3 in soft tissue sarcoma (MPNST) and the effects of perturbing this pathway on tumor cell survival and gene expression. , 2019, , .		0
24	PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma. Neoplasia, 2018, 20, 12-24.	2.3	14
25	APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells. Oncotarget, 2018, 9, 10962-10977.	0.8	29
26	Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival. Scientific Reports, 2018, 8, 13759.	1.6	37
27	Development of a Novel 3D Tumor-tissue Invasion Model for High-throughput, High-content Phenotypic Drug Screening. Scientific Reports, 2018, 8, 13039.	1.6	56
28	Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 108-118.	1.3	33
29	Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition. PLoS ONE, 2018, 13, e0194183.	1.1	31
30	Targeting Ocular Neovascularization with Novel APE1/Refâ€1 Inhibitors. FASEB Journal, 2018, 32, .	0.2	0
31	Abstract 2941: APE1/Ref-1 redox signaling regulates HIF1a-mediated CA9 expression in hypoxic pancreatic cancer cells: Combination treatment in patient-derived pancreatic tumor models. , 2018, , .		0
32	Abstract 4802: Combination therapy in PDAC involving blockade of the APE1/Ref-1 signaling pathway: An investigation into drug synthetic lethality and anti-neuropathy therapeutic approach. , 2018, , .		0
33	Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia. Molecular Cancer Therapeutics, 2017, 16, 1401-1411.	1.9	17
34	<scp>APE</scp>1/Refâ€1 knockdown in pancreatic ductal adenocarcinoma â€“ characterizing gene expression changes and identifying novel pathways using singleâ€cell <scp>RNA</scp> sequencing. Molecular Oncology, 2017, 11, 1711-1732.	2.1	27
35	Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. Npj Precision Oncology, 2017, 1, .	2.3	97
36	Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene, 2017, 36, 1770-1778.	2.6	553

#	Article	IF	Citations
37	Loss of MTSS1 results in increased metastatic potential in pancreatic cancer. Oncotarget, 2017, 8, 16473-16487.	0.8	15
38	Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers. Oncotarget, 2017, 8, 39963-39977.	0.8	38
39	Abstract 5783:In vitromodeling of patient derived bladder cancer cell lines in 3D culture systems. , 2017, , .		0
40	Overview of DNA repair pathways, current targets, and clinical trials bench to clinic. , 2016, , 1-54.		6
41	Regulation of HIF1Î± under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Molecular Cancer Therapeutics, 2016, 15, 2722-2732.	1.9	91
42	Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 300-309.	1.3	48
43	Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer. Neoplasia, 2016, 18, 689-698.	2.3	27
44	Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics. Molecular Cancer Therapeutics, 2016, 15, 794-805.	1.9	35
45	STAT3 in the systemic inflammation of cancer cachexia. Seminars in Cell and Developmental Biology, 2016, 54, 28-41.	2.3	171
46	Abstract 613: Astrocytes and endothelial colony forming cells (ECFCs) influence the migration and drug response of glioblastoma cells in a 3D culture model. , 2016, , .		0
47	Abstract 1246: Development of STAT3 dual-targeting strategies for the treatment of pancreatic cancer. , 2016, , .		0
48	Abstract 4740: Targeting Ref-1/APE1 pathway inhibition in pancreatic cancer using APX3330 for clinical trials. , 2016, , .		0
49	Abstract 5183: Efficacy study of APX3330, a Ref-1 redox inhibitor, and Gemcitabine in a mouse pancreatic ductal adenocarcinoma model. , 2016, , .		0
50	Abstract B51: Regulation of HIF1Î± under hypoxia by APE1/Ref-1 impacts CA9 expression: Dual-targeting in patient-derived 3D pancreatic cancer models. , 2016, , .		1
51	Longitudinal Bioluminescence Imaging of Primary Versus Abdominal Metastatic Tumor Growth in Orthotopic Pancreatic Tumor Models in NSG Mice. Pancreas, 2015, 44, 64-75.	0.5	9
52	Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2. Journal of Biological Chemistry, 2015, 290, 3057-3068.	1.6	57
53	Abstract B158: Targeting APE1/Ref-1 results in inhibition of hypoxia signaling genes. , 2015, , .		3
54	Abstract B19: Redox factor 1 (Ref-1) signaling in the interaction between pancreatic tumor cells and cancer-associated fibroblasts. , 2015, , .		0

#	Article	IF	Citations
55	Targeting DNA repair pathways for cancer treatment: whatâ€™s new?. Future Oncology, 2014, 10, 1215-1237.	1.1	159
56	Development of Selective Inhibitors for Human Aldehyde Dehydrogenase 3A1 (ALDH3A1) for the Enhancement of Cyclophosphamide Cytotoxicity. ChemBioChem, 2014, 15, 701-712.	1.3	51
57	Selective ALDH3A1 Inhibition by Benzimidazole Analogues Increase Mafosfamide Sensitivity in Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 449-461.	2.9	60
58	Abstract 4961: Longitudinal bioluminescence imaging of primary versus abdominal metastatic tumor growth in orthotopic pancreatic tumor models in NOD/SCIDÎ³(-/-) mice. , 2014, , .		0
59	991 APE1/REF-1 REGULATES SURVIVIN-MEDIATED DRUG RESISTANCE IN PROSTATE CANCER CELLS. Journal of Urology, 2013, 189, .	0.2	0
60	Blockade of Base Excision Repair. , 2012, , 29-53.		5
61	APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1. Current Molecular Pharmacology, 2012, 5, 36-53.	0.7	138
62	APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1â€“STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival. PLoS ONE, 2012, 7, e47462.	1.1	84
63	Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth. Molecular Cancer Therapeutics, 2011, 10, 1698-1708.	1.9	92
64	Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell linesÂresults in a hypersensitive response to retinoic acid-induced differentiation and apoptosis. Experimental Hematology, 2010, 38, 1178-1188.	0.2	39
65	Novel Small-Molecule Inhibitor of Apurinic/Apyrimidinic Endonuclease 1 Blocks Proliferation and Reduces Viability of Glioblastoma Cells. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 988-998.	1.3	92
66	Reduced Expression of DNA Repair and Redox Signaling Protein APE1/Ref-1 Impairs Human Pancreatic Cancer Cell Survival, Proliferation, and Cell Cycle Progression. Cancer Investigation, 2010, 28, 885-895.	0.6	50
67	DNA Repair and Redox Signaling. , 2010, , 133-168.		3
68	Abstract 1963: Novel small molecule inhibitor of the endonuclease function of the APE1 DNA repair and redox signaling enzyme blocks proliferation and reduces viability of glioblastoma cells. , 2010, , .		0
69	Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncology, 2009, 5, 713-726.	1.1	36
70	Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: Use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair, 2009, 8, 1273-1282.	1.3	56
71	Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity. DNA Repair, 2009, 8, 1411-1423.	1.3	4
72	Going Ape as an Approach to Cancer Therapeutics. Antioxidants and Redox Signaling, 2009, 11, 651-667.	2.5	100

#	Article	IF	Citations
73	Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair, 2008, 7, 177-186.	1.3	85
74	Role of the Multifunctional DNA Repair and Redox Signaling Protein Ape1/Ref-1 in Cancer and Endothelial Cells: Small-Molecule Inhibition of the Redox Function of Ape1. Antioxidants and Redox Signaling, 2008, 10, 1853-1867.	2.5	145
75	Enhancement of Cisplatin [cis-Diammine Dichloroplatinum (II)] Cytotoxicity by O⁶-Benzylguanine Involves Endoplasmic Reticulum Stress. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 442-452.	1.3	38
76	DNA Repair Proteins as Molecular Targets for Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 417-425.	0.9	94
77	Manipulation of Base Excision Repair to Sensitize Ovarian Cancer Cells to Alkylating Agent Temozolomide. Clinical Cancer Research, 2007, 13, 260-267.	3.2	125
78	The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Molecular Aspects of Medicine, 2007, 28, 375-395.	2.7	244
79	DNA repair in neurons: So if they donâ€™t divide what's to repair?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 614, 24-36.	0.4	216
80	Potentiation of Melphalan-Induced Cytotoxicity through Targeting of the Base Excision Repair Pathway in Multiple Myeloma.. Blood, 2007, 110, 4799-4799.	0.6	0
81	Role of GADD34 in modulation of cisplatin cytotoxicity. Biochemical Pharmacology, 2006, 71, 239-247.	2.0	12
82	Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemotherapy and Pharmacology, 2005, 55, 333-342.	1.1	16
83	Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 206-213.	1.3	21
84	Imbalancing the DNA base excision repair pathway in the mitochondria; targeting and overexpressing N-methylpurine DNA glycosylase in mitochondria leads to enhanced cell killing. Cancer Research, 2003, 63, 608-15.	0.4	64
85	Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Molecular Cancer Therapeutics, 2003, 2, 633-40.	1.9	26
86	Implication of p53 in base excision DNA repair: in vivo evidence. Oncogene, 2002, 21, 731-737.	2.6	106